Usage Examples
- That one is serious and unexpected, so it goes out as a 15-day Alert, not into the periodic.
- We are the applicant here, so this is mandatory MedWatch reporting, not a voluntary submission.
- The investigator filed a MedWatch report on her own before the case ever reached our safety inbox.
What is MedWatch?
MedWatch is FDA's safety reporting program and form set for human medical products, covering both voluntary reports from clinicians and patients and the mandatory postmarket reports sponsors and manufacturers must file under 21 CFR.
MedWatch exists because a premarket dataset of a few thousand subjects cannot surface the rare, delayed, or interaction-driven harms that appear once a product reaches millions of patients. FDA needed one intake channel that a clinician at a bedside and a sponsor's safety department could both use. MedWatch is that channel, and its reports are what turn scattered case observations into a detectable safety signal.
MedWatch covers human medical products across FDA's centers and carries two distinct streams. Voluntary reports come from clinicians, patients, and consumers who owe the agency nothing. Mandatory reports come from applicants, manufacturers, importers, and device user facilities. The boundary matters: MedWatch is the front door and the form set, not the legal obligation. The obligation itself lives in 21 CFR 314.80, 21 CFR 600.80, and 21 CFR Part 803.
MedWatch is applied in practice through a triage decision made case by case. A safety team asks whether the event is serious, whether it is unexpected against the approved labeling, and which regulation governs the product. Serious plus unexpected drives a 15-day Alert report; everything else falls into the periodic report. MedWatch timeliness is what FDA reconstructs on inspection, because every clock has a receipt date behind it.
Not to be confused with
- MDR (Medical Device Reporting)
- MDR is the device-specific mandatory regime at 21 CFR Part 803, running a 30-calendar-day clock. MedWatch is the wider program and form set that MDR submissions travel on, so a device report is both an MDR and a MedWatch report.
- Periodic adverse drug experience reports
- periodic reports are the aggregate channel for everything that is not both serious and unexpected, due quarterly for three years post-approval and annually after. A 15-day Alert report is a separate, expedited channel, not an early version of the periodic.
- IND safety reports
- IND safety reporting covers investigational products still in trials. The MedWatch obligations at 21 CFR 314.80 are postmarketing; the clock in (c)(2)(i) starts from the date of approval of the application.
- FAERS
- FAERS is the database that drug and biologic MedWatch reports land in. MedWatch is the intake pathway; FAERS is what you query afterwards, so "search MedWatch" almost always means "search FAERS."
There is no single MedWatch rule. The obligations sit in the product-specific regulations, and these are the anchors.
What you must do
- 1Report each adverse drug experience that is both serious and unexpected, foreign or domestic, as soon as possible and no later than 15 calendar days from initial receipt of the information21 CFR 314.80(c)(1)(i)
- 2Promptly investigate every event behind a 15-day Alert report and submit follow-up reports within 15 calendar days of receiving new information or when FDA asks21 CFR 314.80(c)(1)(ii)
- 3Report every remaining adverse drug experience at quarterly intervals for 3 years from the date of approval of the application, then at annual intervals21 CFR 314.80(c)(2)(i)
- 4Apply the same 15-calendar-day expedited clock to serious and unexpected adverse experiences for licensed biological products21 CFR 600.80(c)(1)(i)
- 5As a device manufacturer, report no later than 30 calendar days after becoming aware of information from any source that reasonably suggests a device you market caused or contributed to a death or serious injury, or malfunctioned21 CFR 803.50(a)
Common mistakes
Collapsing seriousness and expectedness into one test
they are two independent questions. An event that is serious but already described in approved labeling stays out of the 15-day channel, yet it still has to appear in the periodic report [21 CFR 314.80(c)(2)(i)]. Teams that run one test instead of two drop those cases entirely.
Starting the 15-day clock at safety-database entry
the regulation runs from initial receipt of the information by the applicant, which includes the voicemail to a sales rep and the case sitting in a distribution partner's inbox. Late clocks are the easiest finding for an inspector to prove, because the original receipt date is always somewhere in your records.
Running one clock across a mixed portfolio
drugs and biologics run 15 calendar days; devices run 30 under 21 CFR 803.50(a). A team that standardizes on the 30-day habit files every drug and biologic report roughly two weeks late, and does it consistently enough to show up as a systemic failure rather than a one-off.
When This Matters
- That one is serious and unexpected, so it goes out as a 15-day Alert, not into the periodic.
- We are the applicant here, so this is mandatory MedWatch reporting, not a voluntary submission.
- The investigator filed a MedWatch report on her own before the case ever reached our safety inbox.
Frequently Asked Questions
MedWatch reporting is mandatory for sponsors, manufacturers, importers, and device user facilities, and voluntary for healthcare professionals, patients, and consumers. The mandatory obligation comes from the underlying regulation rather than from MedWatch itself: 21 CFR 314.80 for approved drugs, 21 CFR 600.80 for licensed biologics, and 21 CFR Part 803 for devices.
Related Use Cases
Related Regulatory Intelligence
Related Actions
- Lifecycle Management
Track every sequence operation, amendment, and supplement across the product lifecycle.
- Regulatory Intelligence
Monitor FDA, EMA, ICH, and Health Canada guidance changes across active programs.
- Regulatory Affairs Software
Plan, validate, and execute active submissions in one workspace.
Sources & References
- 21 CFR 314.80 - Postmarketing reporting of adverse drug experiences
- 21 CFR 600.80 - Postmarketing reporting of adverse experiences (biologics)
- 21 CFR 803.50 - Medical Device Reporting: manufacturer reporting requirements
- FDA - MedWatch Forms for FDA Safety Reporting
- FDA - Reporting Serious Problems to FDA
